74%; OR = 1.96; 95% CI 0.79–4.80; p = 0.22). According to the authors, “The higher success rates of trimethoprim–sulfamethoxazole compared with cephalexin were consistent regardless of the presence of wound or abscess, the severity of cellulitis, or whether drainage was performed”. MRSA grew from 72 of the 117 cultures of ulcers or abscesses collected from 129 patients. All 72 isolates were susceptible to trimethoprim–sulfamethoxazole. Streptococci grew from only 9 cultures [31]. A prospective trial by Jeng et al. [10] was published in 2010 and evaluated 179 inpatients with diffuse, non-culturable cellulitis. It included infections on various

regions of the body with the exception of those involving periorbital, perineal, and groin regions. Most cases of cellulitis occurred on the lower extremities. All patients were IWR1 assessed for streptococcal ASO and Screening Library purchase ADB antibodies. This trial was designed to evaluate the efficacy of beta lactams (primarily cefazolin 1 gm q 8 h) without a comparator. One hundred and sixteen of 121 (95.8%) evaluable patients responded to therapy including 21/23 (91%) without evidence of streptococcal infection. Nearly 28% of the study

patients had diabetes mellitus. MRSA colonization was not evaluated. Jenkins and associates retrospectively reviewed discharged patients from a Denver hospital for 2007 using ICD-9 coding data for SSTIs [35]. The

primary outcome of interest was treatment failure. They noted that 85% of patients with cellulitis received anti-MRSA therapy, and nearly half were discharged on a regimen of TMP/SMX. The failure rate for cellulitis was 12%. Most patients were treated with broad-spectrum antibacterial agents, and for a median duration of nearly 2 weeks. The authors suggested SSKI patients would be appropriate for antimicrobial stewardship programs. Jenkins and associates [36] subsequently developed a clinical practice guideline (available as an eFigure in their article) to standardize management of cellulitis and cutaneous abscess at their hospital. Parenteral vancomycin selleckchem was suggested for empirical therapy, along with alternatives to blood cultures. Patients with a discharge diagnosis of cellulitis or cutaneous abscess were compared for 1 year prior to and following implementation of the guideline. Blood culture use declined, as did the use of imaging studies for cellulitis. Vancomycin use increased while beta lactam/beta lactamase inhibitor combinations decreased. On discharge, doxycycline use increased while amoxicillin/clavulanate use decreased. Median duration of antibiotic use decreased from 13 to 10 days. Clinical failure rates did not change. Study of CHIR98014 datasheet Prophylactic Antibiotics for Recurrent Cellulitis A double-blind randomized, controlled trial by Thomas et al. [37] was published in 2013.